Display options
Cite
Gray RT, Cantwell MM, Coleman HG, et al. Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clin Transl Gastroenterol. 2017;8(4):e91doi: 10.1038/ctg.2017.18.
Gray, R. T., Cantwell, M. M., Coleman, H. G., Loughrey, M. B., Bankhead, P., McQuaid, S., O'Neill, R. F., Arthur, K., Bingham, V., McGready, C., Gavin, A. T., Cardwell, C. R., Johnston, B. T., James, J. A., Hamilton, P. W., Salto-Tellez, M., & Murray, L. J. (2017). Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clinical and translational gastroenterology, 8(4), e91. https://doi.org/10.1038/ctg.2017.18
Gray, Ronan T, et al. "Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study." Clinical and translational gastroenterology vol. 8,4 (2017): e91. doi: https://doi.org/10.1038/ctg.2017.18
Gray RT, Cantwell MM, Coleman HG, Loughrey MB, Bankhead P, McQuaid S, O'Neill RF, Arthur K, Bingham V, McGready C, Gavin AT, Cardwell CR, Johnston BT, James JA, Hamilton PW, Salto-Tellez M, Murray LJ. Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clin Transl Gastroenterol. 2017 Apr 27;8(4):e91. doi: 10.1038/ctg.2017.18. PMID: 28448072; PMCID: PMC5543466.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Gastroenterol. 2017 Apr 27;8(4):e91. doi: 10.1038/ctg.2017.18.

Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study.

Clinical and translational gastroenterology

Ronan T Gray, Marie M Cantwell, Helen G Coleman, Maurice B Loughrey, Peter Bankhead, Stephen McQuaid, Roisin F O'Neill, Kenneth Arthur, Victoria Bingham, Claire McGready, Anna T Gavin, Chris R Cardwell, Brian T Johnston, Jacqueline A James, Peter W Hamilton, Manuel Salto-Tellez, Liam J Murray

Affiliations

  1. Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland.
  2. Nutrition and Metabolism Group, Institute for Global Food Security, Queen's University Belfast, Belfast, Northern Ireland.
  3. Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland.
  4. Tissue Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.
  5. Northern Ireland Biobank, Queen's University Belfast, Belfast, Northern Ireland.
  6. Northern Ireland Cancer Registry, Queen's University Belfast, Belfast, Northern Ireland.
  7. Department of Gastroenterology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.

PMID: 28448072 PMCID: PMC5543466 DOI: 10.1038/ctg.2017.18

Abstract

OBJECTIVES: The association between aspirin use and improved survival after colorectal cancer diagnosis may be more pronounced in tumors that have PIK3CA mutations or high PTGS2 expression. However, the evidence of a difference in association by biomarker status lacks consistency. In this population-based colon cancer cohort study the interaction between these biomarkers, aspirin use, and survival was assessed.

METHODS: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008. Aspirin use was determined through clinical note review. Tissue blocks were retrieved to determine immunohistochemical assessment of PTGS2 expression and the presence of PIK3CA mutations. Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer-specific and overall survival.

RESULTS: In this cohort aspirin use was associated with a 31% improvement in cancer-specific survival compared to non-use (adjusted HR=0.69, 95% CI 0.47-0.98). This effect was more pronounced in tumors with high PTGS2 expression (PTGS2-high adjusted HR=0.55, 95% CI 0.32-0.96) compared to those with low PTGS2 expression (PTGS2-low adjusted HR=1.19, 95% CI 0.68-2.07, P for interaction=0.09). The aspirin by PTGS2 interaction was significant for overall survival (PTGS2-high adjusted HR=0.64, 95% CI 0.42-0.98 vs. PTGS2-low adjusted HR=1.28, 95% CI 0.80-2.03, P for interaction=0.04). However, no interaction was observed between aspirin use and PIK3CA mutation status for colorectal cancer-specific or overall survival.

CONCLUSIONS: Aspirin use was associated with improved survival outcomes in this population-based cohort of colon cancer patients. This association differed according to PTGS2 expression but not PIK3CA mutation status. Limiting adjuvant aspirin trials to PIK3CA-mutant colorectal cancer may be too restrictive.

References

  1. Cancer Causes Control. 2012 Dec;23(12):1939-48 - PubMed
  2. Clin Cancer Res. 2012 Jul 1;18(13):3524-31 - PubMed
  3. Gut. 2011 Mar;60(3):397-411 - PubMed
  4. Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26 - PubMed
  5. JAMA Intern Med. 2014 May;174(5):732-9 - PubMed
  6. Int J Cancer. 2010 Jan 15;126(2):382-94 - PubMed
  7. PLoS One. 2016 Apr 20;11(4):e0152402 - PubMed
  8. J Clin Oncol. 2013 Dec 1;31(34):4297-305 - PubMed
  9. Clin Cancer Res. 2012 Dec 1;18(23):6531-41 - PubMed
  10. J Clin Oncol. 2016 Jul 20;34(21):2501-8 - PubMed
  11. BMC Fam Pract. 2010 Jan 05;11:1 - PubMed
  12. BMC Cancer. 2010 Mar 16;10:101 - PubMed
  13. PLoS One. 2012;7(12):e51862 - PubMed
  14. Br J Gen Pract. 2001 Dec;51(473):1001-3 - PubMed
  15. Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):869-76 - PubMed
  16. Lancet. 2012 Apr 28;379(9826):1591-601 - PubMed
  17. Acta Oncol. 2015 Apr;54(4):487-92 - PubMed
  18. Eur J Cancer. 2015 Nov;51(17):2553-61 - PubMed
  19. JAMA. 2011 Jun 8;305(22):2335-42 - PubMed
  20. Lancet. 2009 Apr 11;373(9671):1301-9 - PubMed
  21. Gastroenterology. 2014 Mar;146(3):700-708.e2 - PubMed
  22. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1410-20 - PubMed
  23. Oncogene. 2014 Jun 5;33(23):2949-55 - PubMed
  24. Tumour Biol. 2010 Dec;31(6):623-31 - PubMed
  25. Lancet Oncol. 2012 May;13(5):518-27 - PubMed
  26. N Engl J Med. 2012 Oct 25;367(17):1596-606 - PubMed
  27. JAMA. 2009 Aug 12;302(6):649-58 - PubMed
  28. Cancer Res. 1986 Aug;46(8 Suppl):4244s-4248s - PubMed
  29. Histopathology. 2014 Sep;65(3):340-52 - PubMed
  30. BMJ. 2010 Mar 12;340:b5087 - PubMed
  31. Oncogene. 2008 Sep 18;27(41):5497-510 - PubMed
  32. Gut. 2006 Jan;55(1):62-7 - PubMed
  33. Mod Pathol. 2003 Jan;16(1):79-84 - PubMed

Publication Types